pancreatic caner
Conditions
Interventions
Combination therapy with somatostatin and ulinastatin:Preoperative Combined Use of Ulinastatin and Somatostatin
Control group:No somatostatin or ulinastatin was used before surgery
Sponsors
Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age range from 18 to 75 years old (including boundary values), both male and female. 2. Patients who underwent open pancreaticoduodenectomy in the Department of Hepatobiliary Surgery of Sichuan Provincial People's Hospital and were pathologically confirmed as pancreatic cancer after surgery. 3. ECOG physical status score 0 ~ 1. 4. Subject must sign and date written informed consent. 5. Subjects must be willing and able to comply with the scheduled treatment regimen, laboratory tests, follow-up, and other study requirements.
Exclusion criteria
Exclusion criteria: 1. Preoperative treatment of pancreatic cancer (e.g. interventional, targeted, immunotherapy, etc.). 2. Use ulinastatin or somatostatin alone or in combination for less than 3 days. 3. Patients with missing clinical data and other surgical methods. 4. Pregnant and lactating women. 5. Patients with prior or concurrent other malignant tumors. 6. Participated in other clinical studies within the past 1 month. 7. The investigator assessed the subject's inability or unwillingness to comply with study protocol requirements. 8. The subjects withdrew from the study for various reasons and could not participate in the study again
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| postoperative complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraoperative indicators; | — |
Countries
China
Contacts
Public ContactXiaolun Huang
Sichuan Provincial People's Hospital
Outcome results
None listed